Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Ciglitazone, a new hypoglycaemic agent. 3. effect on glucose disposal and gluconeogenesis in vivo in C57BL/6J-Ob/Ob and — +/? Mice

  • 86 Accesses

  • 18 Citations

Summary

Ciglitazone is orally active in preventing and reversing the hyperglycaemic syndrome in C57BL/6J-ob/ob mice and it is only mildly and transiently hypoglycaemic in lean littermates (C57BL/6J- +/?). Its effect on glucose disposal in vivo was estimated by injecting glucose-6-3H/14C and following the specific activity of radiolabelled glucose at 15, 30, 45, and 60 min after injection. The rate constants of glucose turnover were calculated to be as follows in decreasing order: treated obese (0.046/min), treated lean (0.032/min), control lean (0.026/min), and control obese (0.022/min). The obese mice showed less futile Cori cycle activity than the lean mice and ciglitazone had negligible effect on glucose recycling. The control obese mice incorporated more radiolabels in hepatic lipids, glycogen, and proteins than the control lean mice and ciglitazone further enhanced the incorporations. Ciglitazone also increased hepatic accumulations of radiolabels in the glycogen and lipid fractions in the lean littermates. Using lactate-14C as precursor, gluconeogenesis in vivo was measured in control and treated obese and lean mice. Ciglitazone significantly lowered the rate of conversion of lactate-14C to glucose-14C in the obese mice but not in the lean littermates.

References

  1. 1.

    Chang AY, Wyse BM, Gilchrist BJ, Peterson T, Diani AR (1983) Ciglitazone, a new hypoglycaemic agent I. Studies in the ob/ob and db/db mice, diabetic Chinese hamsters and normal and streptozotocin-diabetic rats. Diabetes 32: 830–838

  2. 2.

    Chang AY, Wyse BM, Gilchrist BJ (1983) Ciglitazone, a new hypoglycaemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and — +/? mice. Diabetes 32: 839–845

  3. 3.

    Dunn A, Chenoweth M, Schaeffer LD (1967) Estimation of glucose turnover and the Cori cycle using glucose 6-t-14C. Biochemistry 6: 6–11

  4. 4.

    Lloyd B, Burrin J, Smythe P, Alberti KGMM (1978) Enzymic fluorometric continuous-flow assays for blood glucose, lactate, pyruvate, alanine, glycerol and 3-hydroxybutyrate. Clin Chem 24: 1724–1729

  5. 5.

    Pollard HB, Stopak SS, Pazoles CJ, Creutz CE (1981) A simple and novel method for radiometric analysis of glucose utilization by adrenal chromaffin cells. Analyt Biochem 110: 424–430

  6. 6.

    Neel JV (1962) Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”? Am J Hum Genet 14: 353–362

  7. 7.

    Coleman DL (1978) Diabetes and obesity, thrifty mutants? Nutr Rev 36: 129–132

  8. 8.

    Coleman DL (1979) Obesity genes: beneficial effects in heterozygous mice. Science 203: 663–665

  9. 9.

    Randle PJ, Garland PB, Hales CN, Newsholme EA (1963) The glucose fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet I: 785–789

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chang, A.Y., Gilchrist, B.J. & Wyse, B.M. Ciglitazone, a new hypoglycaemic agent. 3. effect on glucose disposal and gluconeogenesis in vivo in C57BL/6J-Ob/Ob and — +/? Mice. Diabetologia 25, 514–520 (1983). https://doi.org/10.1007/BF00284462

Download citation

Key words

  • Ciglitazone
  • C57BL/6J-ob/ob mice and their lean littermates
  • glucose turnover rate in vivo
  • gluconeogenesis in vivo
  • Cori cycle